APA (7th ed.) Citation

Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., . . . Tam, C. S. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: The safety run-in of the phase 3 SYMPATICO study. Journal of hematology and oncology, 14(1), 1-8. https://doi.org/10.1186/s13045-021-01188-x

Chicago Style (17th ed.) Citation

Wang, Michael, et al. "Concurrent Ibrutinib Plus Venetoclax in Relapsed/refractory Mantle Cell Lymphoma: The Safety Run-in of the Phase 3 SYMPATICO Study." Journal of Hematology and Oncology 14, no. 1 (2021): 1-8. https://doi.org/10.1186/s13045-021-01188-x.

MLA (9th ed.) Citation

Wang, Michael, et al. "Concurrent Ibrutinib Plus Venetoclax in Relapsed/refractory Mantle Cell Lymphoma: The Safety Run-in of the Phase 3 SYMPATICO Study." Journal of Hematology and Oncology, vol. 14, no. 1, 2021, pp. 1-8, https://doi.org/10.1186/s13045-021-01188-x.